Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
NCT07674615Phase 1Not yet recruiting
- Sponsor
- Shanghai Gynecologic Oncology Group
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sacituzumab govitecan in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by Shanghai Gynecologic Oncology Group. Primary endpoint: Objective Response Rate at 12 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT07674615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674615.